Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Why is Staidson (Beijing) Biopharmaceuticals Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of -10.84% and Operating profit at 8.86% over the last 5 years

With a fall in Operating Profit of -41.61%, the company declared Very Negative results in Sep 25

NET PROFIT(HY) At CNY -28.35 MM has Grown at -406.73%
INVENTORY TURNOVER RATIO(HY) Lowest at 2.47 times
NET SALES(Q) Lowest at CNY 54.94 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 199.73%, its profits have risen by 30.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Staidson (Beijing) Biopharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

209.69%

3.21

89.21%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-10.84%

EBIT Growth (5y)

8.86%

EBIT to Interest (avg)

-201.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

0.33

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.23

EV to EBIT

-239.29

EV to EBITDA

-331.32

EV to Capital Employed

18.60

EV to Sales

64.00

PEG Ratio

Dividend Yield

ROCE (Latest)

-7.77%

ROE (Latest)

-16.57%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at CNY -28.35 MM

RAW MATERIAL COST(Y)

Fallen by -5.38% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -13.35 %

-37What is not working for the Company

NET PROFIT(HY)

At CNY -28.35 MM has Grown at -406.73%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.47 times

NET SALES(Q)

Lowest at CNY 54.94 MM

PRE-TAX PROFIT(Q)

At CNY -8.7 MM has Fallen at -44.78%

INTEREST(Q)

Highest at CNY 4.44 MM

Here's what is working for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Net Profit

Higher at CNY -28.35 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -13.35 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -5.38% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Net Profit

At CNY -28.35 MM has Grown at -406.73%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales

At CNY 54.94 MM has Fallen at -28.5%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Sales

Lowest at CNY 54.94 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Interest

At CNY 4.44 MM has Grown at 2,991.27%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Pre-Tax Profit

At CNY -8.7 MM has Fallen at -44.78%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Inventory Turnover Ratio

Lowest at 2.47 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Interest

Highest at CNY 4.44 MM

in the last five periods and Increased by 2,991.27% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)